Bristol Myers Squibb's Cobenfy Shows Stable Transition Profile in Phase 4 Schizophrenia Trial
核心洞察
Bristol Myers Squibb (搜索) reported Phase 4 data showing 86% of schizophrenia (搜索) patients completed 8 weeks of Cobenfy treatment when switching from oral atypical antipsychotics.
The study demonstrated low discontinuation rates of 13.5-15.1% with no patients stopping due to lack of efficacy, regardless of transition duration.
Cobenfy achieved $155 million in sales during 2025, outpacing comparable schizophrenia (搜索) treatments in its first year following FDA approval in September 2024.
Bristol Myers Squibb (搜索) announced positive Phase 4 clinical trial results for Cobenfy (xanomeline and trospium chloride), demonstrating stable symptom control when transitioning adult schizophrenia (搜索) patients from oral atypical antipsychotics to the novel therapy. The data, presented at the 2026 Annual Congress of the Schizophrenia International Research Society in Florence, Italy, showed that approximately 86% of patients completed the 8-week treatment period.
Trial Design and Primary Outcomes
The Phase 4 study evaluated symptom stability, safety, and tolerability in adult outpatients with schizophrenia (搜索) switching to Cobenfy monotherapy. The primary objective focused on all-cause discontinuation rates over 8 weeks, with patients randomized to either slower or faster cross-titration schedules.
Discontinuation rates remained low at 15.1% for the slower transition group and 13.5% for the faster transition group. Notably, no patients discontinued treatment due to lack of efficacy, indicating maintained therapeutic benefit during the transition period.
Efficacy and Functional Outcomes
Patients demonstrated symptom stability with mean Positive and Negative Syndrome Scale (PANSS) total scores remaining below baseline throughout the study period. Mean changes in PANSS scores from baseline to week 8 were -4.2 in the slower transition group and -3.1 in the faster transition group, indicating modest symptom improvements.
Clinical Global Impression-Severity (CGI-S) scores showed mean changes of -0.2 in both transition groups. Personal and Social Performance (PSP) scores improved by 1.1 and 0.7 points in the slower and faster transition groups, respectively, suggesting maintained or slightly enhanced functional capacity.
Commercial Performance and Market Position
Cobenfy, formerly known as KarXT, represents the first new pharmacological approach to treat schizophrenia (搜索) in decades following FDA approval in September 2024. The drug delivered strong commercial performance in 2025, generating $155 million in sales driven by expanded access and deeper adoption across community and hospital settings.
According to Bristol Myers Squibb (搜索), Cobenfy's uptake has outpaced all comparable schizophrenia (搜索) treatments and relevant analogs in its first year on the market, with continued steady growth expected through 2026. This performance validates the company's acquisition of Karuna Therapeutics (搜索) and strengthens its neuropsychiatry portfolio.
Pipeline Expansion and Future Prospects
Bristol Myers Squibb (搜索) is pursuing multiple label expansions for Cobenfy across various neuropsychiatric conditions. The company has several ongoing Phase III studies in Alzheimer's disease (搜索) patients, including studies in Alzheimer's disease psychosis with data expected in 2026, as well as investigations in agitation and cognitive impairment.
Additional Phase III development includes studies in bipolar I disorder (搜索) and pediatric irritability associated with autism (搜索) spectrum disorder. These expanded indications position Cobenfy as a potential platform therapy across multiple neuropsychiatric conditions.
The company is banking on newer drugs like Cobenfy and Qvantig (搜索) to stabilize its revenue base as legacy products face generic competition, making successful execution of these development programs critical for long-term growth prospects.